Öthman Mezin, Nyholm Dag
Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.
Mov Disord Clin Pract. 2024 Dec;11(12):1609-1612. doi: 10.1002/mdc3.14240. Epub 2024 Oct 24.
Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long-term data are lacking.
To study long-term data on LECIG treatment.
A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.
Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9-30) and 3.6 (3.1-4.0) years, respectively, whereas health-related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8-item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ-5D visual analogue scale scores of 65 (10; n = 7).
LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.
左旋多巴-恩他卡朋-卡比多巴肠凝胶（LECIG）输注于2019年引入瑞典市场，用于治疗有运动波动的帕金森病（PD）。目前缺乏长期数据。
研究LECIG治疗的长期数据。
对2019年至2023年在瑞典接受LECIG治疗的前24例患者进行回顾性分析。
24例患者中有5例（21%）因副作用（主要是腹泻）停用LECIG。24例患者中有8例（33%）在接受LECIG治疗期间死亡。24例患者中有11例（46%）仍在使用LECIG。疾病和治疗持续时间的中位数（范围）分别为19（9 - 30）年和3.6（3.1 - 4.0）年，而健康相关生活质量量表显示帕金森病问卷8项汇总指数得分的中位数（四分位间距；n）为38（4；n = 7），欧洲五维度健康量表（EuroQol 5D）得分为0.59（0.17；n = 7），EQ - 5D视觉模拟量表得分为65（10；n = 7）。
在我们的队列中，LECIG输注是治疗有运动波动的PD患者的一种可行治疗选择，最长可达4年。
